PubRank

J D Iglehart

Author PubWeight™ 76.10‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 1996 2.91
2 Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A 1991 2.27
3 Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991 2.20
4 Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. Cancer Res 1992 1.93
5 Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A 1992 1.87
6 Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. J Biol Chem 1995 1.78
7 A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995 1.62
8 Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 1991 1.58
9 Nonpalpable breast lesions at biopsy. A detailed analysis of radiographic features. Ann Surg 1988 1.55
10 BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ 1996 1.45
11 Use of paravertebral block anesthesia in the surgical management of breast cancer: experience in 156 cases. Ann Surg 1998 1.43
12 Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ 1994 1.42
13 Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995 1.40
14 Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J Natl Cancer Inst 1994 1.39
15 Cell cycle control of BRCA2. Cancer Res 1996 1.32
16 Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 2000 1.31
17 M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene 1996 1.31
18 Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 1991 1.31
19 Local failure and margin status in early-stage breast carcinoma treated with conservation surgery and radiation therapy. Ann Surg 1993 1.27
20 Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer 1998 1.25
21 BRCA1 expression is not directly responsive to estrogen. Oncogene 1997 1.24
22 Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 1989 1.20
23 Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene 1992 1.13
24 Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ 2000 1.13
25 p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem 1992 1.12
26 Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992 1.11
27 Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer. Cold Spring Harb Symp Quant Biol 2005 1.10
28 Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994 1.08
29 Cystosarcoma phyllodes. Effective therapy with cisplatin and etoposide chemotherapy. Cancer 1989 1.06
30 Activated protooncogenes in human lung tumors from smokers. Proc Natl Acad Sci U S A 1991 1.05
31 Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ. J Womens Health Gend Based Med 2001 1.05
32 Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol 1999 1.03
33 Morphological and biochemical properties of a new human breast cancer cell line. Cancer Res 1979 1.02
34 Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin Cancer Res 1996 1.01
35 Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 2001 0.99
36 HIV-1-associated thrombocytopenia. The role of splenectomy. Ann Surg 1990 0.98
37 Pancreaticobronchial fistula. Case report and review of the literature. Gastroenterology 1986 0.97
38 Isolation and initial characterization of the BRCA2 promoter. Oncogene 1999 0.96
39 Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer. Arch Surg 1993 0.94
40 Tissue transglutaminase expression in human breast cancer. Lab Invest 1996 0.94
41 Complex response of breast epithelial cell lines to topoisomerase inhibitors. Anticancer Res 1998 0.92
42 The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer. Cancer 1990 0.92
43 The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg 1995 0.89
44 Quantitative analysis of the transcriptional start sites of estrogen receptor in breast carcinoma. Cell Growth Differ 1995 0.88
45 Prospects for the immunological management of lethal tumors. Cancer Invest 1983 0.85
46 Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. J Clin Oncol 1999 0.84
47 Secretory immune response in patients with oropharyngeal carcinoma. Ann Otol Rhinol Laryngol 1983 0.84
48 p53 alterations in all stages of breast cancer. J Surg Oncol 1991 0.83
49 Predicting breast cancer invasion with artificial neural networks on the basis of mammographic features. Radiology 1997 0.82
50 Response of the secretory immune system to bronchogenic carcinoma of the lung. Surg Forum 1979 0.82
51 Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc Natl Acad Sci U S A 1995 0.82
52 Proliferation index in various stages of breast cancer determined by Ki-67 immunostaining. J Surg Oncol 1991 0.81
53 Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells. Oncogene 1996 0.80
54 Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides. Nucleic Acids Res 1996 0.80
55 Subpopulations of human bronchial epithelial cells in culture respond heterogeneously to 12-O-tetradecanoylphorbol-13-acetate (TPA) and other modulators of differentiation. Carcinogenesis 1987 0.79
56 Mutation analysis of the THRA1 gene in breast cancer: deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line. Cancer Res 1994 0.79
57 Immunotherapy of a murine leukemia virus-infected, chemically induced murine sarcoma with antiviral antibodies. J Natl Cancer Inst 1982 0.79
58 Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. Cancer 1998 0.79
59 DNA ploidy and proliferation index of soft tissue sarcomas determined by image cytometry of fresh frozen tissue. Am J Clin Pathol 1992 0.79
60 Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer. Mod Pathol 1993 0.78
61 Testing for hereditary breast and ovarian cancer in the southeastern United States. Ann Surg 2000 0.78
62 Loss of heterozygosity for genes on 11p and the clinical course of patients with lung carcinoma. Cancer Res 1990 0.78
63 Development of a tracheal implant xenograft model to expose human bronchial epithelial cells to toxic gases. Toxicol Pathol 1989 0.78
64 Elevated serum secretory immunoglobulin A levels in patients with head and neck carcinoma. Otolaryngol Head Neck Surg 1983 0.77
65 An ultrastructural analysis of breast carcinoma presenting as isolated axillary adenopathy. Ann Surg 1982 0.77
66 Genetic counseling for breast cancer. Adv Surg 1999 0.77
67 The emerging genetics of cancer. Surg Gynecol Obstet 1989 0.77
68 Fine-needle aspiration of low grade adenosquamous carcinoma of the breast. Diagn Cytopathol 1996 0.77
69 Bcl10 is not a target for frequent mutation in human carcinomas. Br J Cancer 1999 0.75
70 Carcinogen-induced unscheduled DNA synthesis in xenotransplanted human tracheobronchial epithelium: comparison with rat tracheal epithelium. Carcinogenesis 1988 0.75
71 In vivo antigenic modification of tumor cells. II. Distribution of virus in sarcoma-bearing mice. J Natl Cancer Inst 1981 0.75
72 The natural history of mammographic calcifications subjected to interval follow-up. Arch Surg 1992 0.75
73 In vivo antigenic modification of tumor cells. I. Introduction of murine leukemia virus antigens on non-virus-producing murine sarcomas. J Natl Cancer Inst 1981 0.75
74 Function of the secretory immune system in bronchogenic carcinoma. Immunoglobulin A levels in respiratory secretions. J Thorac Cardiovasc Surg 1981 0.75
75 Preparation of autologous antiserum against SSV nonproducer cells and its partial characterization. Virology 1981 0.75
76 Relative promoter activity in human mammary epithelial cells assayed by transient expression. In Vitro Cell Dev Biol 1993 0.75
77 Detection of a novel marker in the bronchial secretions of patients with non-small cell lung cancer using the 4B5 monoclonal antibody. Cancer 1992 0.75
78 Electron microscopy in selection of patients with small cell carcinoma of the lung for medical versus surgical therapy. J Thorac Cardiovasc Surg 1985 0.75
79 In vivo antigenic modification of tumor cells. III. Metastatic thymic lymphoma specifically infected by thymotropic retrovirus. J Natl Cancer Inst 1981 0.75
80 c-erbB-2 expression in breast cancer detected by immunoblotting and immunohistochemistry. J Histochem Cytochem 1990 0.75
81 The use of a panel of monoclonal antibodies in ultrastructurally characterized small cell carcinomas of the lung. Acta Cytol 1988 0.75
82 Intercellular junctions and tumor stage in small cell carcinoma of the lung. Hum Pathol 1987 0.75
83 Loss of tumorigenicity following in vitro MuLV infection is associated with induction of peritoneal natural killer cell activity. Adv Exp Med Biol 1988 0.75
84 Surgical management of high-risk patients. Breast Dis 2001 0.75
85 Inflammatory breast carcinoma. Effective multimodal approach. Arch Surg 1987 0.75